Trial Profile
ENESTChina: A Phase III Multi-center, Open-label, Randomized Study of Nilotinib Versus Imatinib in Chinese Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENESTChina
- Sponsors Novartis Pharmaceuticals
- 25 Jun 2017 Results (n=59) assessing 12 month response ,presented at the 22nd Congress of the European Haematology Association.
- 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2014 to 1 Oct 2014.